SCHEMBL7146934

SCHEMBL7146934

Nc1nc(NCCc2ccccc2)c(Cl)c(-c2ccco2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.51
ADORA2A P29274 14/20 0.49
ADORA1 P30542 8/20 0.49
ADORA3 P0DMS8 3/20 0.47
ADORA2B P29275 2/20 0.47
NUDT1 P36639 1/20 0.46
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
HPGD P15428 3/20 0.45
GAA P10253 2/20 0.45
GLA P06280 1/20 0.45
HSD17B10 Q99714 1/20 0.45
LMNA P02545 1/20 0.45
STAT6 P42226 1/20 0.45
HIF1A Q16665 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5044498 0.93 ADORA2A (0.50) APPADORA2AADORA1ADORA3ADORA2B
SCHEMBL7151299 0.90 ADORA2A (0.49) ADORA2AADORA1ADORA3ADORA2BALDH1A1
SCHEMBL7397486 0.88 PDE5A (0.51) APPADORA2AADORA1ADORA3ADORA2B
SCHEMBL7169942 0.87 ADORA2A (0.52) APPADORA2AADORA1ADORA3ADORA2B
SCHEMBL7146061 0.87 ADORA2A (0.48) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7146739 0.86 APP (0.51) APPADORA2AADORA1ADORA3ADORA2B
SCHEMBL7151672 0.86 APP (0.51) APPADORA2AADORA1ADORA3ADORA2B
Hydrochloric Acid SCHEMBL7151329 0.85 APP (0.50) APPADORA2AADORA1ADORA3ADORA2B
Hydrochloric Acid SCHEMBL7147946 0.85 APP (0.50) APPADORA2AADORA1ADORA3ADORA2B
SCHEMBL6446426 0.83 ADORA2A (0.60) APPADORA2AADORA1ADORA3ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 APP 477/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.